Total Payments
$7,066
2024 Payments
$2,241
Companies
69
Transactions
323
Medicare Patients
8,231
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$6,653 (94.2%)
Consulting$400.00 (5.7%)
Education$12.60 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,653 | 321 | 94.2% |
| Consulting Fee | $400.00 | 1 | 5.7% |
| Education | $12.60 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $682.29 | 40 | $0 (2024) |
| Daiichi Sankyo Inc. | $634.36 | 11 | $0 (2024) |
| Merck Sharp & Dohme LLC | $410.74 | 21 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $347.79 | 18 | $0 (2024) |
| PFIZER INC. | $298.23 | 16 | $0 (2024) |
| ABBVIE INC. | $290.91 | 14 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $235.82 | 12 | $0 (2024) |
| Lilly USA, LLC | $222.18 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $206.96 | 11 | $0 (2024) |
| Genentech USA, Inc. | $198.05 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,241 | 108 | Novartis Pharmaceuticals Corporation ($234.34) |
| 2023 | $2,323 | 110 | Novartis Pharmaceuticals Corporation ($202.33) |
| 2022 | $491.17 | 22 | Incyte Corporation ($77.19) |
| 2021 | $606.12 | 32 | Novartis Pharmaceuticals Corporation ($131.63) |
| 2020 | $727.64 | 17 | Daiichi Sankyo Inc. ($400.00) |
| 2019 | $105.33 | 5 | Innovation Technologies Inc ($50.00) |
| 2018 | $298.77 | 17 | Pharmacyclics LLC, An AbbVie Company ($40.12) |
| 2017 | $272.67 | 12 | Novo Nordisk Inc ($80.56) |
All Payment Transactions
323 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Oncology | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Hematology | ||||||
| 08/27/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Oncology | ||||||
| 08/15/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $24.66 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: ONCOLOGY | ||||||
| 07/22/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $8.35 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Oncology | ||||||
| 07/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: Oncology | ||||||
| 07/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $0.43 | General |
| Category: Oncology | ||||||
| 06/26/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Oncology | ||||||
| 06/06/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $28.68 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Oncology | ||||||
| 06/04/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: Oncology | ||||||
| 06/03/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $25.93 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $25.56 | General |
| 05/28/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: ONCOLOGY | ||||||
| 05/28/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.48 | General |
| Category: Oncology | ||||||
| 05/24/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 2,994 | 64,343 | $957,652 | $295,465 |
| 2022 | 45 | 2,238 | 53,137 | $746,226 | $226,746 |
| 2021 | 48 | 2,300 | 41,010 | $1.2M | $381,245 |
| 2020 | 10 | 699 | 1,600 | $255,583 | $118,441 |
Total Patients
8,231
Total Services
160,090
Medicare Billing
$1.0M
Procedure Codes
154
All Medicare Procedures & Services
154 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 35 | 4,740 | $127,980 | $87,298 | 68.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 441 | $100,989 | $42,944 | 42.5% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 17 | 3,160 | $69,520 | $19,743 | 28.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 50 | 154 | $58,520 | $15,628 | 26.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 39 | 37,740 | $109,650 | $14,693 | 13.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 83 | 202 | $30,502 | $12,857 | 42.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 104 | 145 | $22,765 | $10,203 | 44.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 86 | 178 | $35,778 | $9,245 | 25.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 11 | 1,160 | $33,640 | $6,358 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $15,505 | $6,271 | 40.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 266 | 711 | $14,220 | $5,951 | 41.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $15,796 | $5,447 | 34.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 234 | 492 | $27,060 | $5,075 | 18.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 35 | $15,085 | $4,991 | 33.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 253 | 655 | $26,200 | $4,972 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 33 | $10,131 | $4,651 | 45.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 95 | 336 | $20,832 | $3,803 | 18.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 29 | $8,555 | $3,114 | 36.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 42 | 236 | $12,744 | $2,997 | 23.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 121 | 213 | $14,910 | $2,800 | 18.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 29 | 121 | $11,495 | $2,755 | 24.0% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 70 | 280 | $13,440 | $2,552 | 19.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 42 | $8,484 | $2,418 | 28.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 25 | 95 | $9,025 | $2,256 | 25.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 24 | $5,232 | $2,251 | 43.0% |
About Dr. Arvind Kumar, MD
Dr. Arvind Kumar, MD is a Hematology & Oncology healthcare provider based in Tinley Park, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861590689.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arvind Kumar, MD has received a total of $7,066 in payments from pharmaceutical and medical device companies, with $2,241 received in 2024. These payments were reported across 323 transactions from 69 companies. The most common payment nature is "Food and Beverage" ($6,653).
As a Medicare-enrolled provider, Kumar has provided services to 8,231 Medicare beneficiaries, totaling 160,090 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 154 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Family Medicine, Medical Oncology
- Location Tinley Park, IL
- Active Since 09/20/2006
- Last Updated 12/04/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1861590689
Products in Payments
- Enhertu (Drug) $528.40
- KEYTRUDA (Biological) $375.52
- LIBTAYO (Biological) $251.42
- KISQALI (Drug) $199.07
- VERZENIO (Drug) $192.30
- Lenvima (Drug) $183.11
- OPDIVO (Biological) $178.33
- OXBRYTA (Drug) $168.27
- VENCLEXTA (Drug) $153.25
- MONJUVI (Drug) $135.90
- ZEPZELCA (Drug) $114.37
- IMBRUVICA (Drug) $111.39
- BRUKINSA (Drug) $105.43
- QINLOCK (Drug) $100.41
- SCEMBLIX (Drug) $94.50
- Xermelo (Drug) $93.39
- LYNPARZA (Drug) $93.29
- CALQUENCE (Drug) $90.13
- MEKINIST (Drug) $80.80
- Tresiba (Drug) $80.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.